What is HC Wainwright's Estimate for MNPR Q1 Earnings?

Key Points

• HC Wainwright forecast a Q1 2027 loss of $0.91 per share for Monopar Therapeutics and projected losses of $1.05, $1.19 and $1.15 per share in Q2, Q3 and Q4, respectively. The firm maintained its Buy rating.
• Monopar reported a quarterly loss of $0.72 per share, narrower than analysts’ expected loss of $0.82, beating consensus by $0.10.
• Analyst sentiment is broadly positive: MarketBeat lists a “Moderate Buy” consensus and an average price target of $122.78, based on seven Buy, one Hold and one Sell rating.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - HC Wainwright issued their Q1 2027 earnings per share estimates for Monopar Therapeutics in a note issued to investors on Thursday, November 12th. HC Wainwright analyst A. Maldonado expects that the company will earn ($0.91) per share for the quarter. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($2.98) per share. HC Wainwright also issued estimates for Monopar Therapeutics' Q2 2027 earnings at ($1.05) EPS, Q3 2027 earnings at ($1.19) EPS and Q4 2027 earnings at ($1.15) EPS.

MNPR has been the subject of several other reports. Morgan Stanley reiterated an "overweight" rating and issued a $130.00 price target on shares of Monopar Therapeutics in a research note on Monday, August 17th. BTIG Research reissued a "buy" rating on shares of Monopar Therapeutics in a report on Thursday. Wall Street Zen cut Monopar Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, October 10th. UBS Group set a $125.00 price target on Monopar Therapeutics in a research note on Thursday, July 23rd. Finally, Barclays reaffirmed an "overweight" rating and set a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $122.78.

Monopar Therapeutics Stock Up 1.3%

Shares of MNPR opened at $72.68 on Friday. Monopar Therapeutics has a 12 month low of $50.07 and a 12 month high of $124.82. The firm's 50 day moving average is $83.52 and its 200-day moving average is $77.40.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.10.

Insider Activity

In other Monopar Therapeutics news, Director Raymond Anderson sold 3,142 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the transaction, the director directly owned 23,751 shares in the company, valued at $2,654,649.27. The trade was a 11.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the company's stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the sale, the chief executive officer owned 99,267 shares of the company's stock, valued at $8,735,496. The trade was a 22.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,920 shares of company stock valued at $4,527,913 in the last three months. Company insiders own 9.70% of the company's stock.

Institutional Trading of Monopar Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp grew its position in Monopar Therapeutics by 24.1% in the third quarter. State Street Corp now owns 229,771 shares of the company's stock valued at $18,306,000 after acquiring an additional 44,669 shares during the last quarter. Siren L.L.C. lifted its holdings in shares of Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company's stock worth $14,800,000 after acquiring an additional 57,820 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock worth $14,480,000 after acquiring an additional 30,370 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Monopar Therapeutics in the second quarter worth about $7,124,000. Finally, Walleye Capital LLC acquired a new stake in shares of Monopar Therapeutics in the 1st quarter valued at approximately $3,458,000. 1.83% of the stock is currently owned by institutional investors.

More Monopar Therapeutics News

Here's some of the latest news about MNPR:

• Positive Sentiment: Cantor Fitzgerald upgraded MNPR from “Neutral” to “Overweight” and set a $119 price target, signaling a more bullish view of the stock. Monopar Therapeutics Stock Moved Up to Overweight by Cantor Fitzgerald
• Positive Sentiment: Monopar reported a third-quarter loss of $0.72 per share, narrower than analysts’ expected loss of $0.82, beating consensus by $0.10. Monopar Reports Third Quarter 2026 Results and Business Updates
• Neutral Sentiment: HC Wainwright maintained its “Buy” rating and forecast quarterly losses of $0.91–$1.19 per share for 2027. The continued projected losses temper the positive signals, while the estimates do not indicate a change to its rating.

About Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.